Dmitry Balyasny’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.68M | Sell |
20,605
-439,959
| -96% | -$31.8M | ﹤0.01% | 1910 |
|
|
2026
Q1 | $31.4M | Buy |
+460,564
| New | +$32.6M | 0.04% | 507 |
|
|
2025
Q4 | – | Sell |
-95,925
| Closed | -$5.89M | – | 3473 |
|
|
2025
Q3 | $5.89M | Buy |
+95,925
| New | +$5M | 0.01% | 1296 |
|
|
2024
Q4 | – | Sell |
-62,549
| Closed | -$2.32M | – | 3167 |
|
|
2024
Q3 | $2.32M | Buy |
+62,549
| New | +$2.09M | ﹤0.01% | 1609 |
|
|
2023
Q2 | – | Sell |
-91,436
| Closed | -$4.43M | – | 2682 |
|
|
2023
Q1 | $4.43M | Sell |
91,436
-9,496
| -9% | -$434K | 0.01% | 1129 |
|
|
2022
Q4 | $3.85M | Buy |
+100,932
| New | +$4.2M | 0.01% | 1139 |
|
|
2022
Q2 | – | Sell |
-109,402
| Closed | -$4.08M | – | 3087 |
|
|
2022
Q1 | $4.08M | Buy |
109,402
+25,980
| +31% | +$1M | 0.01% | 1031 |
|
|
2021
Q4 | $3.32M | Sell |
83,422
-24,870
| -23% | -$952K | 0.01% | 999 |
|
|
2021
Q3 | $4.03M | Sell |
108,292
-136,540
| -56% | -$5.61M | 0.02% | 895 |
|
|
2021
Q2 | $10.3M | Buy |
+244,832
| New | +$10.5M | 0.05% | 508 |
|
|
2020
Q4 | – | Sell |
-5,489
| Closed | -$257K | – | 1618 |
|
|
2020
Q3 | $257K | Sell |
5,489
-2,109
| -28% | -$104K | ﹤0.01% | 1187 |
|
|
2020
Q2 | $386K | Buy |
+7,598
| New | +$373K | ﹤0.01% | 962 |
|
|
2019
Q4 | – | Sell |
-93,122
| Closed | -$3.15M | – | 1424 |
|
|
2019
Q3 | $3.15M | Buy |
93,122
+3,084
| +3% | +$134K | 0.02% | 635 |
|
|
2019
Q2 | $4.05M | Sell |
90,038
-68,713
| -43% | -$2.71M | 0.03% | 669 |
|
|
2019
Q1 | $5.97M | Buy |
+158,751
| New | +$5.33M | 0.04% | 532 |
|
|
2018
Q4 | – | Sell |
-700,692
| Closed | -$32.9M | – | 1676 |
|
|
2018
Q3 | $32.9M | Buy |
700,692
+392,931
| +128% | +$16.3M | 0.15% | 186 |
|
|
2018
Q2 | $10.4M | Buy |
307,761
+81,228
| +36% | +$2.53M | 0.05% | 482 |
|
|
2018
Q1 | $6.13M | Buy |
+226,533
| New | +$5.74M | 0.03% | 652 |
|
|
2017
Q4 | – | Sell |
-15,100
| Closed | -$302K | – | 2254 |
|
|
2017
Q3 | $302K | Buy |
+15,100
| New | +$296K | ﹤0.01% | 1533 |
|
|
2016
Q4 | – | Sell |
-330,000
| Closed | -$4.62M | – | 1459 |
|
|
2016
Q3 | $4.62M | Buy |
+330,000
| New | +$2.68M | 0.03% | 517 |
|
|
2015
Q2 | – | Sell |
-83,218
| Closed | -$5.06M | – | 1287 |
|
|
2015
Q1 | $5.06M | Sell |
83,218
-103,677
| -55% | -$6.33M | 0.04% | 475 |
|
|
2014
Q4 | $9.68M | Buy |
+186,895
| New | +$8.23M | 0.09% | 302 |
|
|
2014
Q3 | – | Sell |
-41,820
| Closed | -$1.09M | – | 833 |
|
|
2014
Q2 | $1.09M | Buy |
+41,820
| New | +$895K | 0.01% | 587 |
|
Other funds holding PTCT
RI
JT
Dmitry Balyasny's PTCT Position: Q2 2026 in Review
Dmitry Balyasny reduced its PTC Therapeutics (PTCT) stake by 96% in Q2 2026, selling an estimated $31.8M and leaving 20,605 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1910.
Dmitry Balyasny first reported a position in PTCT in Q2 2014 and has held it in 23 quarters since. The position peaked at $32.9M in Q3 2018. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Dmitry Balyasny held 20,605 shares of PTC Therapeutics worth $1.68M as of Q2 2026.
- Dmitry Balyasny sold 439,959 PTC Therapeutics shares in Q2 2026, an estimated $31.8M.
- PTC Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1910 holding.
- Dmitry Balyasny first reported a position in PTC Therapeutics in Q2 2014 and has held it in 23 quarters since.
- Dmitry Balyasny's PTC Therapeutics position peaked at $32.9M in Q3 2018.
- 380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.